Search results
Results from the WOW.Com Content Network
1942 – gramicidin S, the first peptide antibiotic; 1942 – sulfadimidine; 1943 – sulfamerazine; 1944 – streptomycin, the first aminoglycoside [2] 1947 – sulfadiazine; 1948 – chlortetracycline, the first tetracycline; 1949 – chloramphenicol, the first amphenicol [2] 1949 – neomycin; 1950 – oxytetracycline; 1950 – penicillin G ...
Cefiderocol may cause serious and life-threatening allergic reactions, severe diarrhea caused by C. difficile and seizures. [9]An increased rate of mortality was observed in people treated with cefiderocol as compared to other antibiotics in a separate clinical trial in critically ill people with multidrug-resistant Gram-negative bacterial infections.
Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB).
The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic . Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing.
Cresomycin is an experimental antibiotic.It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria, and it has been found to be effective against multi-drug-resistant stains of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. [1]
Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005. [25] In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without additional studies, and an EU application was withdrawn. [citation needed]
Antibiotics don't work at all on viruses — the most common cause of pink eye. And even mild eye infections from bacteria will resolve on their own in most cases, the medical group says.
Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections in combination with probenecid (Brand name: Orlynvah).